" A United Nations panel recently released disastrous policy recommendations designed to increase access to medicines in developing countries. The panel ignored obvious solutions. Secretary General Ban Ki-Moon originally tasked the UN High-Level Panel on Access to Medicines with remedying the “policy incoherence” between intellectual property rights and drug access. The panel predictably — and wrongly — viewed IP protections as a barrier to access rather than a bridge to medical innovation. Undermining IP rights will not help patients in developing countries access medicines. A 2016 Foreign Affairs study sought to determine whether strong patent protections increase the prices of drugs to developing countries. It found that patents were not key drivers of higher expenditures."
Issues and developments related to IP, AI, and OM, examined in the IP and tech ethics graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology", coming in Summer 2025, includes major chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Kip Currier, PhD, JD
Wednesday, November 2, 2016
Patent rights key to ensuring access to medication; Trib Live, 10/24/16
Robert A. Freeman, Trib Live; Patent rights key to ensuring access to medication:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment